TGA Change Impact Assessment for Australian Medical Device Approval

The TGA assesses whether a medical device meets applicable Australian regulatory requirements for safety, performance, classification, conformity assessment evidence, labeling, and inclusion in the ARTG. For post-approval changes, the TGA also considers whether updates to design, software, manufacturing, materials, or intended purpose affect the basis on which the device was originally approved and supplied in Australia.

TGA assessment is the regulatory review process used to determine whether a medical device and its supporting evidence satisfy Australian requirements under the Therapeutic Goods framework. Depending on the situation, this can involve reviewing classification, technical documentation, conformity assessment evidence, sponsor arrangements, labeling, risk management, and whether a proposed device change requires notification, variation, or a new ARTG application.

A TGA change impact assessment is needed whenever an ARTG-listed device undergoes a meaningful update to design, materials, manufacturing process, software, labeling, sterilization, intended purpose, or supply configuration. The assessment determines whether the change affects safety, performance, or the original conformity assessment basis, and whether regulatory action is required before implementation or continued supply in Australia.

Changes that may trigger TGA action include modifications to device design, raw materials, manufacturing sites or processes, software functionality, indications for use, labeling content, packaging, sterilization methods, and conformity assessment evidence. The key issue is whether the change alters the approved device in a way that affects compliance, safety, performance, or the regulatory basis of the ARTG inclusion.

Yes. Labeling and IFU changes can affect Australian approval if they alter intended purpose, claims, warnings, mandatory content, presentation, or UDI-related obligations. Even when a change appears administrative, it should be reviewed against TGA requirements such as Schedule 1 expectations and applicable labeling guidance to confirm whether the update can proceed as documented or needs formal regulatory action.

Elexes documents the nature of the proposed change, the affected device elements, the regulatory framework applied, the conformity assessment implications, and the final determination. The output is a structured, defensible record that can support internal change control, sponsor review, audit readiness, and any required TGA notification, variation, or new application activity tied to the assessed change.

Not every software change requires a new TGA application, but software updates should always be assessed carefully. Changes to algorithms, intended use, clinical functionality, cybersecurity controls, user interface behavior, or performance claims can alter the regulatory position of the device. A formal impact assessment helps determine whether the update is manageable within existing approval or triggers further TGA action.

Timing depends on the complexity of the device, the number of affected documents, and whether the change touches multiple regulatory elements such as labeling, risk management, software, and manufacturing. Straightforward assessments can move quickly once documentation is available, while complex portfolio or multi-market changes take longer. The goal is a complete, evidence-based determination rather than a rushed opinion that creates later regulatory exposure.